Now enrolling patients! NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) is a clinical trial that analyzes patients’ tumors to determine whether they contain genetic abnormalities for which a targeted drug exists and assigns treatment based on the abnormality.
A Joint Meeting by EORTC, NCI, EMA and AACR
3-4 December 2015 (Brussels, Belgium)
Notice of Proposed Rulemaking:
Federal Policy for the Protection
of Human Subjects
On September 8, DHHS published in the Federal Register a notice of proposed rulemaking to revise the federal regulations protecting human research subjects.
Welcome to the Cancer Diagnosis Program!
The Cancer Diagnosis Program strives to improve the diagnosis and assessment of cancer by effectively moving new scientific knowledge into clinical practice. This national program stimulates, coordinates and funds resources and research for the development of innovative in vitro diagnostics, novel diagnostic technologies and appropriate human specimens in order to better characterize cancers and allow improved medical decision making and evaluation of response to treatment.
For more information about the Cancer Diagnosis Program and its Branches, please click here.
News and Announcements
There are currently no scheduled events